Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Annals of Surgical Oncology

Volumn 14, Issue 8, 2007, Pages 2300-2308

  Baratti, Dario ^a   Kusamura, Shigeki ^a   Martinetti, Antonia ^a   Seregni, Ettore ^a   Laterza, Barbara ^a   Oliva, Daniela G ^a,b   Deraco, Marcello ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

CA125; CA19.9; HIPEC; Hyperthermic intraperitoneal chemotherapy; Peritonectomy; Pseudomyxoma peritonei; Serum tumor markers

Indexed keywords

CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; MITOMYCIN C; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; FEMALE; HISTOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERITONEUM PSEUDOMYXOMA; PROGNOSIS; SEX; SURVIVAL; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; RADIOGRAPHY, ABDOMINAL; RADIOGRAPHY, THORACIC; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34547479234     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9393-9     Document Type: Article

References (33)

1. Sugarbaker PH. Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994; 219:109-11
2. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7:69-76
3. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997; 16:1-9
4. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112-9
5. Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg 1980; 115:409-14
6. Sugarbaker PH. Cytoreductive surgery and intra-peritoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Eur J Surg 1991; 561(Suppl.):75-82
7. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12:765-77
8. Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727-31
9. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458-63
10. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11:393-8
11. Bagshawe KD, Rustin GJ. Circulating tumour markers. In Peckham M, Pinedo H, Veronesi U (Eds). Oxford Textbook of Oncology, Oxford: Oxford University Press, 1995:412-20
12. Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961-7
13. Carmignani CP, Hampton R, Sugarbaker CE, et al. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004; 87:162-6
14. Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 2005; 7:382-6
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55
16. Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 1995; 181:530-8
17. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am 2003; 12:703-27
18. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, sites of origin, prognosis and relationship to pesudomixoma peritonei. Am J Surg Pathol 1995; 19:1390-408
19. Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321-5
20. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49-58
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457-81
23. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187-220
24. Jacquet P, Stephens AD, Averbach DM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77:2622-9
25. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10:863-9
26. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: analysis of morbidity and mortality in 209 cases treated with closed abdomen technique. Cancer 2006; 106:1144-53
27. Verwaal VJ, van Tinteren H, Ruth SV, et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-7
28. Barlow TS, Przybylski M, Schilder JM, et al. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006; 16:496-500
29. Fehm T, Jager W, Kramer S, et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004; 24:1987-92
30. Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei. Surg Gynecol Obstet 1992; 175:401-4
31. Nasr MF, Kemp GM, Given PT Jr. Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil. Eur J Gynaecol Oncol 1993; 14:213-7
32. Esquivel J, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg 2001; 234:198-205
33. Choi MY, Lee KM, Chung JK, et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 2005; 19:123-9